Clin2
NCT07700719Likely a fitNot yet recruiting

New drug SHR-A1904 for advanced colorectal cancer

Colorectal Cancer Metastatic

Treatments studied

Part of Cancer clinical trials.

This study tests a new drug called SHR-A1904 for people with advanced colorectal cancer that has not responded to at least two prior treatments. It aims to see if this drug can help shrink or control the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
17 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must be between 18 and 75 years old.
  • You must have colorectal cancer that has spread to other parts of the body (metastatic).
  • You must have already tried at least two prior standard chemotherapy treatments, including oxaliplatin, irinotecan, and fluoropyrimidine (like 5-FU).
  • You need to have a tumor that can be measured on scans (at least one measurable spot).
  • You should be in good enough health to take care of yourself (ECOG score 0 or 1).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06679673Not yet recruiting· Phase 2
Study of three drugs for metastatic colorectal cancer

This trial tests a combination of three drugs (SHR-1701, SHR2554, and BP102) to see if they work better together for people with metastatic colorectal cancer. It is for those who have not been treated with similar immune checkpoint drugs before.

Shanghai, Shanghai Municipality
NCT07050394Recruiting· Early Phase 1
Experimental drug for advanced colorectal cancer

This trial tests a new experimental drug (HNF4α srRNA) given through a vein for people with advanced colorectal cancer that has not responded to or cannot be treated with standard therapies. The goal is to see if this treatment can help shrink or slow the growth of the cancer.

Shanghai, None Selected
NCT07520357Not yet recruiting· Phase 2
Testing SHR-A1904 for Advanced Neuroendocrine Cancer

This study tests a new drug called SHR-A1904 for patients with advanced neuroendocrine cancer (a rare type of cancer) who have already tried at least one round of chemotherapy. The goal is to see if this drug can slow or shrink the cancer.

Beijing, Beijing Municipality
NCT07676162Not yet recruiting· Phase 3
New targeted drug combo for advanced colorectal cancer

This trial tests a new targeted drug (SHR-A1811) combined with chemotherapy and bevacizumab versus the usual therapy for advanced colorectal cancer that hasn't been treated yet. It aims to see if the new combo works better as a first treatment.

Beijing, Beijing Municipality
NCT06417554Recruiting· Phase 1/Phase 2
Study of SHR-A2102 for advanced solid tumors

This trial is testing a new drug, SHR-A2102, either alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to see if it can shrink tumors or slow the cancer's growth.

Beijing, Beijing Municipality
NCT07515820Not yet recruiting· Phase 2
SHR-3821 for Advanced Colorectal Cancer That Didn't Respond to Prior Treatment

This study tests a new drug called SHR-3821 in patients with colorectal cancer that has spread or come back after at least two rounds of standard chemotherapy. The goal is to see if this drug can slow or shrink the cancer.

Hear when a new Colorectal Cancer Metastatic trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.